Myeloid malignancies exhibit profound metabolic dependence on mitochondrial oxidative phosphorylation (OXPHOS) for survival and proliferation. Antileukemic therapies such as Venetoclax combined with Azacitidine or cytarabine induce rapid mitochondrial collapse, disrupting electron transport, NADH oxidation, and ATP synthesis, followed by a selective rebound of fatty-acid oxidation (FAO) and redox-buffering programs that sustain minimal residual disease. This review integrates current mechanistic and clinical insights into therapy-induced mitochondrial suppression, delineates the regulatory circuitry that enables metabolic recovery, and frames these events as a reversible model of clinical energy deficiency. By linking mitochondrial stress signaling, lipid oxidation, and adaptive redox metabolism, we outline how bioenergetic reprogramming drives therapeutic resistance and propose interventions that target this adaptive axis in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and related myeloid neoplasms.
1 August 2026 in Journal of Clinical Medicine Research
Background: Acute kidney injury (AKI) is common in cardiogenic shock and is associated with poor outcomes. Whether routinely available inflammatory indices add useful information for AKI risk stratification in this population remains unclear. Methods: We performed a retrospective multicenter cohort study using the eICU Collaborative Research Database. Adult intensive care unit (ICU) patients with cardiogenic shock were included if laboratory components required to calculate inflammatory indices were available. All indices were derived from a single set of laboratory values obtained on ICU admission rather than from serial measurements. AKI was defined using creatinine-based Kidney Disease: Improving Global Outcomes criteria and renal replacement therapy status. We evaluated neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, monocyte to lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, aggregate index of systemic inflammation, and neutrophil percentage to albumin ratio. Missing covariate data were handled using multiple imputation. Multivariable logistic regression, false discovery rate correction, elastic-net analysis, calibration, and decision-curve analysis were used to assess associations and incremental discrimination. Results: The final cohort included 419 patients, of whom 273 (65.1%) developed AKI. Baseline creatinine was the strongest variable associated with AKI in the primary multivariable model. Chronic kidney disease was associated with AKI when creatinine and blood urea nitrogen were excluded. Inflammatory indices were not independently associated with AKI after multivariable adjustment and false discovery rate correction. The base clinical model had modest discrimination, which improved after adding renal laboratory variables. Adding inflammatory indices provided little to no meaningful incremental discrimination, and inflammatory indices were not consistently retained in elastic-net models. Conclusion: In this multicenter ICU cohort of patients with cardiogenic shock, AKI was associated mainly with baseline renal dysfunction and illness severity. Routine inflammatory indices did not provide meaningful incremental discrimination beyond established clinical and renal variables for AKI during ICU hospitalization. These findings apply to blood count-derived indices and do not exclude a contribution of inflammation to AKI in cardiogenic shock.
1 January 2025 in Critical Care Research and Practice
Background: Prolonged use of intravenous (IV) vasopressors in critically ill patients is associated with significant complications. Droxidopa, a norepinephrine precursor approved for neurogenic orthostatic hypotension, has gained interest as an off‐label agent for facilitating vasopressor weaning in ICU settings. This systematic review aimed to evaluate the efficacy and safety of droxidopa for vasopressor weaning in ICU patients. Methods: A systematic review was conducted following PRISMA guidelines. Databases searched included PubMed, Embase, Cochrane, and Web of Science through April 2025. Eligible studies reporting primary clinical data on droxidopa use in ICU patients were included. Outcomes included time to IV vasopressor discontinuation, duration of droxidopa use, ICU length of stay (LOS), and ICU mortality, and results were narratively synthesized. The risk of bias was assessed using the ROBINS‐I and the JBI checklists. Results: Seven studies involving 161 ICU patients were included. Five studies reported time to vasopressor discontinuation, ranging from 29 to 120 h. The duration of droxidopa use ranged from 87 to 192 h. Two studies reported ICU LOS, ranging from 18 to 44 days. ICU mortality was inconsistently reported. These findings are primarily drawn from small, retrospective studies and should be interpreted cautiously. Discussion: Findings suggest that droxidopa may effectively facilitate vasopressor weaning in critically ill patients. However, variations in dosing, patient selection, and outcome reporting limit generalizability. Evidence is drawn primarily from small, retrospective studies, some available only as abstracts. Conclusion: Available evidence on droxidopa for vasopressor weaning in ICU patients remains limited and heterogeneous, with very low certainty. Further research is warranted. No funding was received for this review, and the review was not prospectively registered.